Key facts
- Ai-Brainscience’s last known valuation is $55.1M (Nov 2023).
- It has raised $10.3M; the latest was Later Stage VC in Feb 2026.
- Notable investors include SBI Investment, Nippon Venture Capital, Osaka University Venture Capital, Bio Sight Capital, Capita (Japan) — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Ai-Brainscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Ai-Brainscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ai-Brainscience
Developer of an eye-tracking cognitive assessment technology designed to enable early detection and evaluation of cognitive impairment and dementia. The company's platform offers AI-based analysis of eye movements through low-stress and quantitative testing methods, enabling healthcare providers and older adults to assess cognitive function objectively and support early intervention.
- Sector
- Healthcare
- HQ
- Suita, Japan
- Founded
- 2019
- Website
- ai-brainscience.co.jp/
- Ownership
- Privately Held (backing)
Ai-Brainscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ai-Brainscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ai-Brainscience in its N-PORT filings yet. We sweep new filings monthly.